GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valiant Laboratories Ltd (BOM:543998) » Definitions » Capex-to-Operating-Income

Valiant Laboratories (BOM:543998) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Valiant Laboratories Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Valiant Laboratories's Capital Expenditure for the three months ended in Dec. 2024 was ₹0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was ₹1.02 Mil.

Hence, Valiant Laboratories's Capex-to-Operating-Income for the three months ended in Dec. 2024 was 0.00.


Valiant Laboratories Capex-to-Operating-Income Historical Data

The historical data trend for Valiant Laboratories's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valiant Laboratories Capex-to-Operating-Income Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Capex-to-Operating-Income
0.04 0.17 1.12 -

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Valiant Laboratories's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valiant Laboratories's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's Capex-to-Operating-Income falls into.


;
;

Valiant Laboratories Capex-to-Operating-Income Calculation

Valiant Laboratories's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-458.703) / -103.732
=N/A

Valiant Laboratories's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 1.021
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valiant Laboratories  (BOM:543998) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Valiant Laboratories Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Valiant Laboratories's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Valiant Laboratories Business Description

Traded in Other Exchanges
Address
Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.

Valiant Laboratories Headlines

No Headlines